arrow
F

Faı̈ez Zannad

INSERM
H指数:148
被引数:16.5万
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MAGGIC and PREDICT-HF Models in the VICTOR Trial: Do Traditional Risk Scores Still Work in Well-Treated Ambulatory Patients with HFrEF?

MAGGIC和PREDICT-HF模型在VICTOR试验中:传统风险评分在治疗良好的HFrEF门诊患者中是否仍然有效?

2026-09-210
PRE
Mortality benefit and lifetime survival gains with vericiguat in HFrEF: Bayesian and actuarial analyses of the VICTOR trial

维利卡格在HFrEF中的死亡率效益和终身生存获益:VICTOR试验的贝叶斯和精算分析

2026-09-160
OAAI
Efficacy of vericiguat by background guideline-directed medical therapy in the VICTOR trial

在VICTOR试验中,vericiguat在背景指南导向药物治疗下的疗效

2026-09-080
OAAI
Low-Normal Hemoglobin Concentrations and Clinical Outcomes in Heart Failure

低正常血红蛋白浓度与心力衰竭的临床结局

2026-08-280
PRE
Finerenone benefits in patients with cardio-kidney-metabolic syndrome with or without history of cancer: the FINE-HEART pooled analysis

在有无癌症病史的心肾代谢综合征患者中非奈利酮的获益:FINE-HEART合并分析

2026-08-180
OAAI
Finerenone and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction

非奈利酮对射血分数轻度降低或保留的心力衰竭患者中表观治疗抵抗性高血压的影响

2026-08-170
OAAI
Spironolactone in the Treatment of Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Design and Baseline Characteristics of the SPIRIT-HF-DZHK08 Trial

螺内酯在轻度射血分数降低或保留的心力衰竭治疗中的应用:SPIRIT-HF-DZHK08试验的设计和基线特征

2026-07-280
OAAI
Sleep Apnea in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

心力衰竭伴轻度降低或保留射血分数时的睡眠呼吸暂停

2026-06-230
PRE
Effects of Finerenone on Sudden Death Across the Cardio-Kidney-Metabolic Landscape

非奈利酮对心血管-肾脏-代谢全景中猝死的影响

JACC
IF0
2026-06-030
OAAI
Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis

心力衰竭患者的最佳血清钾浓度:一项个体患者数据Meta分析

2026-05-280
PRE